Abstract
Despite major advances in therapy of hepatitis C over the past decade, nearly half of the patients treated with the currently available regimens do not clear the virus. Therefore, there is a large unmet need for more effective therapy for patients who have failed pegylated interferon plus ribavirin therapy. We describe a case of a HCV genotype 1b patient who had failed previous combination therapies of interferon plus ribavirin and pegylated interferon plus ribavirin and was subsequently successfully treated with a novel triple drug combination consisting of interferon-γ plus interferon alfacon plus ribavirin with the outcome of a sustained virologic response. This triple drug therapy combination could be an option for patients who have failed therapies with currently available pegylated interferons plus ribavirin. Prospective randomized studies are required to evaluate the effectiveness and tolerability of this regimen in this patient population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965, 2001
Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982, 2002
Blatt LM, Davis JM, Klein SB, et al.: The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 16:489–499, 1996
Fauci AS, Rosenberg SA, Sherwin SA, et al.: Immunomodulators in clinical medicine. Ann Intern Med 106:421–433, 1987
Wang T, Ozes O, Tan H, et al.: The combination of type 1 (IFN Alfacon-1) and type 2 (IFN Gamma-1b) interferons enhances Th1 and natural killer cell responses: implications for resolution of chronic HCV infection in difficult-to-treat patients. Gastroenterology 128:S925, 2005
Frese M, Schwarzle V, Barth K, et al.: Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35:694–703, 2002
Di Bisceglie AM, Rustgi VK, Kassianides C, et al.: Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 11:266–270, 1990
Carreno V, Moreno A, Galiana F, et al.: Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study. J Hepatol 17:321–325, 1993
Musch E, Hogemann B, Gerritzen A, et al.: Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Hepatogastroenterology 45:2282–2294, 1998
De Mulder PH, Oosterhof G, Bouffioux C, et al.: EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer 71:371–375, 1995
Janson ET, Kauppinen HL, Oberg K: Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial. Acta Oncologica 32:231–233, 1993
Halme M, Maasilta PK, Pyrhonen SO, et al.: Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer—a randomised study. Eur J Cancer 30A:11–15, 1994.
Fujii A, Yui-En K, Ono Y, et al.: Preliminary results of the alternating administration of natural interferon-alpha and recombinant interferon-gamma for metastatic renal cell carcinoma. BJU Int 84:399–404, 1999
Halme M, Knuuttila A, Vehmas T, et al.: High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 80:1781–1785, 1999
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Balan, V., Rosati, M.J., Anderson, M.H. et al. Successful Treatment With Novel Triple Drug Combination Consisting of Interferon-γ, Interferon Alfacon-1, and Ribavirin in a Nonresponder HCV Patient to Pegylated Interferon Therapy. Dig Dis Sci 51, 956–959 (2006). https://doi.org/10.1007/s10620-006-9349-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9349-0